Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease-Reference-Cited by-同舟云学术

Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease

Published:2019-04-30 Issue:4 Volume:39 Page:414-420
ISSN:0271-9142
Container-title:Journal of Clinical Immunology
language:en
Short-container-title:J Clin Immunol

Author:

Al-Saud Bandar^ORCID,Al-Saleem Alhanouf,Al Rasheed Bashayer,Al-Ghonaium Abdulaziz,Al-Ahmari Ali,Al-Mousa Hamoud,Al-Seraihy Amal,Arnaout Rand,Al-Jefri Abdullah,Elshorbagi Sahar,Elsayed Nazeema,Al-Dhekri Hasan,Ayas Mouhab,Al-Muhsen Saleh

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s10875-019-00634-3.pdf

Reference20 articles.

1. Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092–8.

2. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–55.

3. Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013;33:1156–64.

4. Wahlstrom JT, Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Curr Pediatr Rep. 2015;3:1–10.

5. Paczesny S. Graft-versus-host disease in children after hematopoietic cell transplantation: potential clinical utility of biomarkers. Int J Hematol Oncol. 2015;4(2):51–4.